Abstract:The field of stem cell biology and regenerative medicine is rapidly moving toward translation to clinical practice, and in doing so has become even more dependent on animal donors and hosts for generating cellular reagents and assaying their potential therapeutic efficacy in models of human disease. Advances in cell culture technologies have revealed a remarkable plasticity of stem cells from embryonic and adult tissues, and transplantation models are now needed to test the ability of these cells to protect at-risk cells and replace cells lost to injury or disease. With such a mandate, issues related to acceptable sources and controversial (e.g., chimeric) models have challenged the field to provide justification of their potential efficacy before the passage of new restrictions that may curb anticipated breakthroughs. Progress from the use of both in vitro and in vivo regenerative medicine models already offers hope both for the facilitation of stem cell phenotyping in recursive gene expression profile models and for the use of stem cells as powerful new therapeutic reagents for cancer, stroke, Parkinson's, and other challenging human diseases that result in movement disorders. This article describes research in support of the following three objectives: (1) To discover the best stem or progenitor cell in vitro protocols for isolating, expanding, and priming these cells to facilitate their massive propagation into just the right type of neuronal precursor cell for protection or replacement protocols for brain injury or disease, including those that affect movement such as Parkinson's disease and stroke; (2) To discover biogenic factors--compounds that affect stem/progenitor cells (e.g., from high-throughput screening and other bioassay approaches)--that will encourage reactive cell genesis, survival, selected differentiation, and restoration of connectivity in central nervous system movement and other disorders; and (3) To establish the best animal models of human disease and injury, using both small and large animals, for testing new regenerative medicine therapeutics.

Disease in a Dish: Using Stem Cells to Study Human Diseases

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Embryonic stem cell application in drug discovery

Induced Pluripotent Stem Cells As a Disease Modeling and Drug Screening Platform

Human Induced Pluripotent Stem Cell for Modeling Cardiovascular Diseases.

[Progress in the Derivation, Culture of Human Embryonic Stem Cells].

Disease research and drug development models based on genetically altered human embryonic stem cells.

Embryonic Stem Cells: New Possible Therapy for Degenerative Diseases That Affect Elderly People.

Stem cells, regenerative medicine, and animal models of disease

Developing Humanized Animal Models with Transplantable Human iPSC-Derived Cells

Human tissues in a dish: The research and ethical implications of organoid technology

Clinical trials in-a-dish for cardiovascular medicine

Disease modelling in human organoids

Stem cells, organoids and their applications for human diseases: Special issue of BMB Reports in 2023

Can stem-cell-derived models revolutionize drug discovery?

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery

Human organoids: model systems for human biology and medicine

Stem Cells in Development of Therapeutics for Parkinson's Disease: a Perspective.

Stem Cell-Based Disease Modeling and Cell Therapy

Organoids as preclinical models of human disease: progress and applications

A brief chronicle of research on human pluripotent stem cells